A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: Treatment of involuntary emotional expression disorder
暂无分享,去创建一个
[1] C. Sánchez,et al. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression , 1997, Psychopharmacology.
[2] R. Matsumoto. Sigma Receptors: Chemistry, Cell Biology And Clinical Implications , 2007 .
[3] L. Werling,et al. Modulation of Classical Neurotransmitter Systems by σ Receptors , 2007 .
[4] Daniel Weintraub,et al. Defining and Diagnosing Involuntary Emotional Expression Disorder , 2006, CNS Spectrums.
[5] K. Metters,et al. Binding of [3H]cimetidine to rat brain tissue , 1980, Agents and Actions.
[6] S. Bunn,et al. Effects of thyroid status on presynapticα2-adrenoceptor function andβ-adrenoceptor binding in the rat brain , 2005, Journal of Neural Transmission.
[7] R. Thisted,et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine , 2004, Neurology.
[8] E. Sellers,et al. Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers , 2004, Journal of clinical pharmacology.
[9] W. Danysz,et al. Brain Penetration and In Vivo Recovery of NMDA Receptor Antagonists Amantadine and Memantine: A Quantitative Microdialysis Study , 1999, Pharmaceutical Research.
[10] L. Werling,et al. Acute and chronic effects of nicotine on serotonin uptake in prefrontal cortex and hippocampus of rats , 2003, Synapse.
[11] W. Slikker,et al. Adolescent nicotine administration alters serotonin receptors and cell signaling mediated through adenylyl cyclase , 2002, Brain Research.
[12] D. Mash,et al. Dopamine transport function is elevated in cocaine users , 2002, Journal of neurochemistry.
[13] G. Miller,et al. Transgenic expression of a mutant glycine receptor decreases alcohol sensitivity of mice. , 2002, The Journal of pharmacology and experimental therapeutics.
[14] A R Damasio,et al. Pathological laughter and crying: a link to the cerebellum. , 2001, Brain : a journal of neurology.
[15] N. Bowery,et al. Allosteric modulation of [3H]‐CGP39653 binding through the glycine site of the NMDA receptor: further studies in rat and human brain , 2001, British journal of pharmacology.
[16] Weimin Hong,et al. Evidence that the σ1 receptor is not directly coupled to G proteins , 2000 .
[17] M. Rogawski,et al. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents – toward an understanding of their favorable tolerability , 2000, Amino Acids.
[18] Yueh-Ching Chou,et al. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan , 1999, Brain Research.
[19] R. Blakely,et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.
[20] R. Bridges,et al. Irreversible Inhibition of High‐Affinity [3H]Kainate Binding by a Novel Photoactivatable Analogue: (2′S,3′S,4′R)‐2′‐Carboxy‐4′‐(2‐Diazo‐1‐Oxo‐3,3,3‐Trifluoropropyl)‐3′‐Pyrrolidinyl Acetate , 1997, Journal of neurochemistry.
[21] F. Tortella,et al. An autoradiographic study of dextromethorphan high‐affinity binding sites in rat brain: sodium‐dependency and colocalization with paroxetine , 1997, British journal of pharmacology.
[22] H S Chen,et al. Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism. , 1997, The Journal of physiology.
[23] G. Steinberg,et al. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. , 1996, Journal of neurosurgery.
[24] C. Parsons,et al. Zinc changes AMPA receptor properties: Results of binding studies and patch clamp recordings , 1996, Neuropharmacology.
[25] S. Deben,et al. Functional and Binding Properties of σ Receptors in Rat Cerebellum , 1995 .
[26] J. Kornhuber,et al. Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man , 1995, Neuroscience Letters.
[27] K. Kellar,et al. Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. , 1995, Molecular pharmacology.
[28] E. Meier,et al. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. , 1995, Journal of medicinal chemistry.
[29] K. Kovács,et al. Density of NMDA‐Coupled and Uncoupled 1‐[1‐(2‐[3H]Thienyl)cyclohexyl]piperidine Recognition Sites in the Brain and Spinal Cord: Differential Effects of NMDA Agonists and Antagonists , 1994, Journal of neurochemistry.
[30] E. Richelson. Pharmacology of antidepressants--characteristics of the ideal drug. , 1994, Mayo Clinic proceedings.
[31] R. Rosenthal,et al. Increased Activation of L‐Type Voltage‐Dependent Calcium Channels Is Associated with Glycine Enhancement of N‐Methyl‐d‐Aspartate‐Stimulated Dopamine Release in Global Cerebral Ischemia/Reperfusion , 1994, Journal of neurochemistry.
[32] E. Wong,et al. Different densities of 5-HT3 receptors are labeled by [3H]quipazine, [3H]GR 65630 and [3H]geanisetron , 1993, Neuropharmacology.
[33] P. Pflimlin,et al. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. , 1993, European journal of pharmacology.
[34] R. DeLaPaz,et al. Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. , 1993, Neurological research.
[35] D. Hosford,et al. Increased number of GABAB receptors in the lethargic (lh/lh) mouse model of absence epilepsy , 1993, Brain Research.
[36] G. F. Steinfels,et al. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles. , 1992, The Journal of pharmacology and experimental therapeutics.
[37] K. Sudoh,et al. Characterization of [3H]YM617, R-(-)-5-[2-[[2[ethoxyring(n)-3H](o-ethoxyphenoxy)ethyl]amino]- propyl]-2-methoxybenzenesulfonamide HCl, a potent and selective alpha-1 adrenoceptor radioligand. , 1992, The Journal of pharmacology and experimental therapeutics.
[38] S. Tejani-butt. [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. , 1992, The Journal of pharmacology and experimental therapeutics.
[39] E. Wong,et al. Identification of a novel NMDA receptor in rat cerebellum. , 1991, European journal of pharmacology.
[40] Y. Hattori,et al. Identification and characterization of histamine H1‐ and H2‐receptors in guinea‐pig left atrial membranes by [3H]‐mepyramine and [3H]‐tiotidine binding , 1991, British journal of pharmacology.
[41] K. Baimbridge,et al. Dextromethorphan and phencyclidine receptor ligands: Differential effects on K+- and NMDA-evoked increases in cytosolic free Ca2+ concentration , 1991, Neuroscience Letters.
[42] M. Johnston,et al. Pharmacology of N‐methyl‐D‐aspartate‐induced brain injury in an in vivo perinatal rat model , 1990, Synapse.
[43] F. Tortella,et al. Dextromethorphan and neuromodulation: old drug coughs up new activities. , 1989, Trends in pharmacological sciences.
[44] D. Greenberg,et al. Antagonist drug selectivity for radioligand binding sites on voltage-gated and N-methyl-d-aspartate receptor-gated Ca2+ channels , 1989, Neuroscience Letters.
[45] P. Canoll,et al. Dextromethorphan and sigma ligands: common sites but diverse effects. , 1989, Life sciences.
[46] R. Kostrzewa,et al. Impaired ontogeny of striatal dopamine D1 and D2 binding sites after postnatal treatment of rats with SCH-23390 and spiroperidol. , 1989, Brain research. Developmental brain research.
[47] D. Greenberg,et al. Dextromethorphan and dextrorphan as calcium channel antagonists , 1988, Brain Research.
[48] D. Choi,et al. Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. , 1987, The Journal of pharmacology and experimental therapeutics.
[49] G. Wooten,et al. Effects of sodium on cell surface and intracellular 3H-naloxone binding sites. , 1987, Life sciences.
[50] D. Choi. Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity , 1987, Brain Research.
[51] T. Inaba,et al. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. , 1986, British journal of clinical pharmacology.
[52] W. Stigelman,et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .
[53] S. Snyder,et al. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1- propyl)piperidine , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[54] P. Sever,et al. Heterogeneity of mammalian α2-adrenoceptors delineated by [3H]yohimbine binding , 1986 .
[55] L. M. Zhang,et al. Dextrorphan: an antagonist for phencyclidine receptor. , 1986, NIDA research monograph.
[56] J. Bircher,et al. Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.
[57] K. Kuriyama,et al. Some characteristics of [3H]muscimol binding to synaptic membrane from rat brain , 1980, Brain Research.
[58] S. Snyder,et al. The glycine synaptic receptor: evidence that strychnine binding is associated with the ionic conductance mechanism. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[59] S. Snyder,et al. Muscarinic cholinergic binding in rat brain. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[60] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .